Garo H. Armen - Jun 18, 2025 Form 4 Insider Report for AGENUS INC (AGEN)

Role
Chairman and Chief Executive Officer, Director
Signature
/s/Christine M. Klaskin, as Attorney-in-Fact for Garo H. Armen
Stock symbol
AGEN
Transactions as of
Jun 18, 2025
Transactions value $
$290,800
Form type
4
Date filed
6/30/2025, 04:30 PM
Previous filing
Jun 20, 2025
Next filing
Jul 15, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ARMEN GARO H Chairman and Chief Executive Officer, Director C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON /s/Christine M. Klaskin, as Attorney-in-Fact for Garo H. Armen 2025-06-30 0000935679

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGEN Common Stock Award $274K +61.4K +31.65% $4.47 255K Jun 18, 2025 Direct F1, F2
transaction AGEN Common Stock Award $16.4K +3.44K +1.35% $4.76 259K Jun 27, 2025 Direct F3, F4
holding AGEN Common Stock 31.3K Jun 18, 2025 See Footnote F5
holding AGEN Common Stock 29K Jun 18, 2025 See Footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the executive's 2024 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a 30-day lockup restriction with 100% of the award released on July 18, 2025.
F2 $4.47 was the fair market value of Agenus Common Stock on June 18, 2025, the stock issuance date.
F3 At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 27, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.
F4 $4.76 is the closing price of our Common Stock on June 27, 2025, the last trading day for the payroll date for the pay period ending June 27, 2025.
F5 Shares are held in Dr. Armen's IRA accounts.
F6 Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.

Remarks:

Chairman and Chief Executive Officer